Company reports Quarterly reportsAnnual reports PresentationsAnnouncementsAnnual General MeetingFinancial calendarCorporate governanceData of sharesConferences, roadshowsAnalystsContact Latest reports Richter Group Report - 3 months to March 2020580 kb 05/08/2020let lt sGedeon Richter Annual report 20191499 kb 04/09/2020let lt sGedeon Richter Consolidated Financial Statements 20192335 kb 04/09/2020let lt s Latest announcements Composition of share capital and voting rights05/29/20Payment of dividends by Chemical Works of Gedeon Richter Plc.05/14/20Richter-Helm Biologics and INOVIO will expand existing DNA manufacturing agreement to support large-scale manufacturing of Inovio’s investigational DNA vaccine for COVID-1904/30/20Richter-Helm Biologics, Gedeon Richter Plc. ("Richter") and Helm AG's joint venture microbial biotechnology contract development and cGMP manufacturing organization, today announced it has entered into an agreement with US based INOVIO (NASDAQ: INO) to expand its manufacturing partnership in order to support large-scale manufacturing of INOVIO's investigational DNA vaccine for COVID-19, INO-4800, which is currently in Phase 1 clinical testing in the U.S. and and could potentially advance to Phase 2/3 efficacy trials this summer.
Latest reports Richter Group Report - 3 months to March 2020580 kb 05/08/2020let lt sGedeon Richter Annual report 20191499 kb 04/09/2020let lt sGedeon Richter Consolidated Financial Statements 20192335 kb 04/09/2020let lt s
Richter-Helm Biologics and INOVIO will expand existing DNA manufacturing agreement to support large-scale manufacturing of Inovio’s investigational DNA vaccine for COVID-1904/30/20Richter-Helm Biologics, Gedeon Richter Plc. ("Richter") and Helm AG's joint venture microbial biotechnology contract development and cGMP manufacturing organization, today announced it has entered into an agreement with US based INOVIO (NASDAQ: INO) to expand its manufacturing partnership in order to support large-scale manufacturing of INOVIO's investigational DNA vaccine for COVID-19, INO-4800, which is currently in Phase 1 clinical testing in the U.S. and and could potentially advance to Phase 2/3 efficacy trials this summer.
